Drugs / CT327
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01243307 | Jan → Apr 2011 | neuropathy, painful | Creabilis SA | Completed | No outcome recorded |
| Phase 1 | NCT01243502 | Sep → Nov 2007 | — | Creabilis SA | Completed | No outcome recorded |
| Phase 1 | NCT01368315 | — | atopic eczema | Creabilis SA | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01808157 | Jul 2013 → Apr 2014 | atopic eczema | Creabilis SA | Completed | No outcome recorded |
| Phase 2 | NCT01465282 | Dec 2011 → Sep 2012 | psoriasis | Creabilis SA | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03448081 Comparator | Feb → Nov 2018 | psoriasis | Sienna Biopharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03322137 Comparator | Oct 2017 → Sep 2018 | psoriasis | Sienna Biopharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00996008 Comparator | Nov 2009 → Oct 2010 | atopic eczema | Creabilis SA | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT 327 | “Positive responders to the APT test will enter into a treatment period of ten days during which all subjects will have three test compounds (CT 327, Placebo or an active...” NCT01368315 ↗ |
| Known as | Pegcantratinib | “SNA-120 (Pegcantratinib) Ointment” NCT03322137 ↗1“SNA-120 (Pegcantratinib) Ointment” NCT03448081 ↗ |
| Known as | Pegylated K-252 | “A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of the Safety and Efficacy of CT 327, Pegylated K-252, Formulated as a Cream, When Administered...” NCT00996008 ↗ |
| Known as | SNA-120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03322137 ↗ |
| Action | Inhibit | “inhibitor of nerve growth factor (NGF)” NCT01243502 ↗ |
| Route | Topical | “0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily” NCT00996008 ↗ |
| Target | NGF | “inhibitor of nerve growth factor (NGF)” NCT01243502 ↗ |